Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

Running, not enrolling · Phase 3

Conditions studied: Relapsed/Refractory Follicular Lymphoma

In brief

The goal of this clinical study is test how well the study drug, axicabtagene ciloleucel, works in participants with relapsed/refractory follicular lymphoma

Key facts

Study ID
NCT05371093
Run by
Kite, A Gilead Company
People needed
231
Starts
2022-09-22
Expected to finish
2030-10-01
Last updated by the study team
2025-10-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.